Eli Lilly and Company (NYSE:LLY) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Eli Lilly and Company (NYSE:LLY) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $815.00 target price on the stock. Cantor Fitzgerald also issued estimates for Eli Lilly and Company’s FY2024 earnings at $12.10 EPS.

Several other equities research analysts have also commented on LLY. Truist Financial reissued a buy rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. TheStreet raised shares of Eli Lilly and Company from a c+ rating to a b rating in a research note on Friday, March 8th. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an outperform rating in a research note on Wednesday, February 7th. Citigroup lifted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a buy rating in a report on Tuesday, April 2nd. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a hold rating to a buy rating in a report on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $728.05.

Eli Lilly and Company Trading Up 0.6 %

Shares of LLY opened at $750.87 on Monday. The firm’s 50-day moving average price is $764.03 and its 200-day moving average price is $657.67. The firm has a market capitalization of $713.45 billion, a price-to-earnings ratio of 129.46, a PEG ratio of 1.64 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the previous year, the firm posted $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by corporate insiders.

Institutional Trading of Eli Lilly and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Simon Quick Advisors LLC boosted its position in shares of Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after purchasing an additional 278 shares during the period. Clear Harbor Asset Management LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $363,000. WASHINGTON TRUST Co boosted its position in shares of Eli Lilly and Company by 16.5% in the fourth quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after purchasing an additional 2,671 shares during the period. Liontrust Investment Partners LLP bought a new position in shares of Eli Lilly and Company during the third quarter worth $8,326,000. Finally, Redhawk Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 0.9% during the third quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock worth $3,752,000 after acquiring an additional 65 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.